Your browser is no longer supported. Please, upgrade your browser.
Settings
OCGN Ocugen, Inc. daily Stock Chart
OCGN [NASD]
Ocugen, Inc.
Index- P/E- EPS (ttm)-6.03 Insider Own7.80% Shs Outstand16.63M Perf Week-14.02%
Market Cap7.72M Forward P/E- EPS next Y-0.36 Insider Trans- Shs Float13.72M Perf Month-30.65%
Income-33.50M PEG- EPS next Q-0.14 Inst Own9.20% Short Float11.62% Perf Quarter50.31%
Sales- P/S- EPS this Y76.40% Inst Trans105.93% Short Ratio0.22 Perf Half Y-96.23%
Book/sh-2.04 P/B- EPS next Y90.20% ROA-284.40% Target Price1.63 Perf Year-94.13%
Cash/sh- P/C- EPS next 5Y- ROE604.20% 52W Range0.23 - 21.60 Perf YTD-10.71%
Dividend- P/FCF- EPS past 5Y38.20% ROI- 52W High-97.85% Beta2.52
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low97.57% ATR0.06
Employees49 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)40.61 Volatility9.82% 10.21%
OptionableNo Debt/Eq- EPS Q/Q-116.50% Profit Margin- Rel Volume0.22 Prev Close0.51
ShortableYes LT Debt/Eq- EarningsMar 03 BMO Payout- Avg Volume7.25M Price0.46
Recom2.00 SMA20-15.89% SMA50-14.06% SMA200-92.90% Volume1,574,246 Change-9.14%
Feb-10-20 07:30AM  Ocugen to Present at NobleCon16 - Noble Capital Markets Sixteenth Annual Investor Conference GlobeNewswire +9.65%
Jan-03-20 02:44PM  3 Beaten-Up Biotech Stocks That Just Got More Enticing TipRanks +5.54%
Dec-09-19 09:29AM  Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD GlobeNewswire -5.88%
Nov-08-19 07:30AM  Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights GlobeNewswire -13.79%
Nov-06-19 09:01AM  Ocugen Announces Warrant Restructuring GlobeNewswire -9.66%
Nov-04-19 07:30AM  Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards GlobeNewswire
Oct-25-19 07:30AM  Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights GlobeNewswire -7.37%
Oct-23-19 08:30AM  Ocugen Appoints Jessica Crespo, CPA, as Controller GlobeNewswire
Oct-09-19 07:30AM  Ocugen Announces Share Repurchase Program GlobeNewswire +34.38%
Oct-07-19 07:00AM  Ocugen Announces Amendment to Asset Purchase Agreement GlobeNewswire
Oct-01-19 07:30AM  Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer GlobeNewswire -23.16%
Sep-30-19 04:05PM  Ocugen to Present at Three Upcoming Conferences GlobeNewswire -70.68%
08:30AM  Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing Business Wire
07:30AM  Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Business Wire
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Musunuri ShankarChief Executive OfficerDec 12Buy0.35143,00050,050406,000Dec 13 08:44 PM
Musunuri ShankarChief Executive OfficerDec 11Buy0.41263,000107,830263,000Dec 13 08:44 PM
Zhang JungeDirectorDec 04Buy0.44220,00096,800818,578Dec 05 02:01 PM
Zhang JungeDirectorNov 27Buy0.37270,00099,900600,078Dec 02 07:37 AM
Zhang JungeDirectorNov 25Buy0.27115,00031,050330,078Nov 26 07:18 PM
Zhang JungeDirectorNov 22Buy0.2880,00022,400215,078Nov 26 07:18 PM
Subramanian SanjayChief Financial OfficerNov 22Buy0.285,0001,40010,000Nov 26 07:17 PM
Zhang JungeDirectorNov 18Buy0.41100,00041,000135,078Nov 20 06:31 PM